Related Experiment Videos
Therapy of infantile spasms with valproate: results of a prospective study
Insights
Sodium valproate (VPA) effectively controlled infantile spasms in most children. This study found VPA monotherapy achieved seizure freedom in 20 of 22 patients within six months, demonstrating its therapeutic potential.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Infantile spasms (IS) are a severe epilepsy syndrome in infants.
- Sodium valproate (VPA) is a broad-spectrum antiepileptic drug with established efficacy in various seizure types.
Purpose of the Study:
- To evaluate the efficacy and safety of sodium valproate (VPA) in treating infantile spasms (IS).
- To assess VPA monotherapy and adjunctive treatments for IS control.
Main Methods:
- Prospective study of 22 children with recently diagnosed infantile spasms.
- Treatment initiated with VPA, with dosage titration up to 100 mg/kg/day.
- Adjunctive dexamethasone or carbamazepine (CBZ) used if VPA monotherapy failed.
Main Results:
- Infantile spasms were controlled in 11 children after 4 weeks of VPA monotherapy.
- Seizure freedom achieved in 16 of 22 children after 3 months (14 on VPA monotherapy).
- Total seizure control reached in 20 of 22 patients after 6 months, with 16 on VPA monotherapy.
Conclusions:
- Sodium valproate (VPA) is an effective first-line treatment for infantile spasms (IS).
- VPA monotherapy provides significant seizure control in a majority of patients.
- Adjunctive therapies may be necessary for refractory cases.
Abstract:
In a prospective study, 22 children with recently manifested infantile spasms (18 patients with symptomatic and 4 with idiopathic infantile spasms) were treated with sodium valproate (VPA). Before VPA was instituted, a loading test was performed to exclude abnormal patterns of VPA metabolites by gas chromatography and mass spectroscopy of serum and urine. This test was repeated during VPA therapy; an abnormal pattern of VPA metabolites was not observed. VPA was started in increasing dosage until infantile spasms were controlled or a maximum dose of 100 mg/kg/day was reached. If VPA did not control seizures or at least reduce frequency significantly after a trial of 4-6 weeks, dexamathasone was added to VPA. If focal seizures occurred in association with localized epileptogenic EEG discharges, carbamazepine (CBZ) was added to VPA. After 4 weeks of VPA monotherapy, infantile spasms were controlled in 11 children. After 3 months of therapy, 16 children were free of seizures (14 patients VPA monotherapy), and 4 children had reduction of seizure frequency to less than 25%. VPA doses varied between 40 and 100 mg/kg/day (mean 74). The mean plasma concentration was 113 micrograms/ml (range 46-177). After 6 months of therapy, total seizure control was achieved in 20 of 22 patients (16 children VPA monotherapy). The mean observation time was 16 1/2 months (range 6-36 months). There were seven relapses in six children during the first 7 months of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)